ONX-0914 (PR-957): Selective Immunoproteasome LMP7 Inhibitor for Autoimmune Research

Executive Summary: ONX-0914 (PR-957) is a potent, selective inhibitor of the immunoproteasome LMP7 (β5i) subunit, with minimal effect on constitutive β5 activity in human and mouse cells. This compound robustly reduces proinflammatory cytokine secretion, including IL-23, TNF-α, and IL-6, in PBMCs and inhibits IL-17-producing T cells under Th17-polarizing conditions (Kondakova et al., 2025). In vivo, ONX-0914 attenuates disease in mouse models of arthritis, diabetes, and colitis via dose-dependent reduction of autoantibodies and cartilage breakdown markers. ONX-0914 is insoluble in water but dissolves at ≥29.03 mg/mL in DMSO and ≥69 mg/mL in ethanol, facilitating cell and animal studies. APExBIO provides ONX-0914 (SKU A4011) as a validated research tool for immunoproteasome studies and cytokine modulation [product link].

Biological Rationale

The ubiquitin-proteasome system (UPS) is central to cellular protein homeostasis and regulated degradation. The immunoproteasome, a specialized variant of the proteasome, incorporates the inducible LMP7 (β5i) subunit, replacing the constitutive β5 subunit in response to cytokine signaling, notably IFN-γ. Immunoproteasome activity is enriched in immune cells and elevated in inflamed tissues, contributing to antigen processing and shaping cytokine profiles (Kondakova et al., 2025). Targeting immunoproteasome-specific subunits, such as LMP7, enables selective modulation of immune responses while sparing general proteasome function and minimizing cytotoxicity associated with pan-proteasome inhibitors. This selectivity is particularly relevant in autoimmune diseases, where dysregulated cytokine production and antigen presentation drive pathology.

Mechanism of Action of ONX-0914 (PR-957)

ONX-0914 (PR-957) is a peptide epoxyketone inhibitor that binds covalently and selectively to the catalytic threonine of the LMP7 subunit within the immunoproteasome. This binding induces conformational changes in the S1 substrate binding pocket, effectively blocking the chymotrypsin-like proteolytic activity unique to LMP7, while sparing the β5 subunit of the constitutive proteasome in both human and mouse cells. As a result, ONX-0914 disrupts the generation of specific antigenic peptides and impairs the production of key proinflammatory cytokines, such as IL-23, TNF-α, and IL-6, in peripheral blood mononuclear cells (PBMCs). This targeted action leads to reduced activation and differentiation of Th17 cells and modulation of the overall immune response (Kondakova et al., 2025). Notably, ONX-0914 does not significantly interfere with the constitutive proteasome, thus maintaining essential proteostatic functions in non-immune tissues.

Evidence & Benchmarks

• ONX-0914 (PR-957) binds selectively to LMP7 (β5i), not β5, in human and mouse cells, as demonstrated by activity-based protein profiling and substrate specificity assays (Kondakova et al., 2025).
• Application of ONX-0914 results in the suppression of IL-23, TNF-α, and IL-6 release from PBMCs in vitro, with efficacy at 200 nM following 1-hour incubation (Kondakova et al., 2025).
• In Th17-polarizing conditions, ONX-0914 robustly inhibits IL-17-producing T cell differentiation (Kondakova et al., 2025).
• In mouse models of diabetes, arthritis, and colitis, intravenous ONX-0914 dosing (2–10 mg/kg) significantly delays or attenuates disease progression and reduces biomarkers such as autoantibodies and cartilage breakdown products (Kondakova et al., 2025).
• ONX-0914 is insoluble in water but soluble at ≥29.03 mg/mL in DMSO and ≥69 mg/mL in ethanol, supporting both in vitro and in vivo experimental protocols (APExBIO product page).
• Immunoproteasome subunit (PSMB8-10) expression and activity correlate with key markers (Ki67, ER, PR) in breast cancer subtypes, supporting the rationale for selective targeting (Kondakova et al., 2025).

This article extends the mechanistic and translational context provided by "ONX-0914 (PR-957): Redefining Immunoproteasome Inhibition", by offering a granular, citation-backed evidence summary tailored to autoimmune models and practical laboratory workflows.

For a focused discussion on selective LMP7 targeting in arthritis and diabetes, readers should see "ONX-0914: Selective Immunoproteasome Inhibitor for Precis..."; the present review provides updated solubility, dosing, and benchmarking data for ONX-0914 (PR-957).

Applications, Limits & Misconceptions

ONX-0914 (PR-957) is primarily employed in research involving:

• Autoimmune disease modeling (e.g., mouse models of arthritis, diabetes, colitis).
• Cytokine production blockade in immune cells.
• Investigation of immunoproteasome function and antigen processing.
• Dissecting caspase-independent cell death pathways in immune regulation.

Common Pitfalls or Misconceptions

• ONX-0914 is not a pan-proteasome inhibitor: It does not significantly inhibit the constitutive β5 subunit and should not be used where broad proteasome inhibition is required.
• Not suitable for water-based stock solutions: ONX-0914 is insoluble in water; use DMSO or ethanol for solution preparation.
• Long-term solution storage is discouraged: Compound stability decreases in solution; prepare fresh working aliquots for each experiment (APExBIO).
• Therapeutic extrapolation caution: ONX-0914 is a research-use-only compound and not approved for clinical or diagnostic use.
• Cell-type specificity: Efficacy and selectivity are best established in immune-derived cells and validated preclinical models; results may not generalize to all tissue types.

Workflow Integration & Parameters

ONX-0914 (A4011) is available from APExBIO as a research-grade reagent (product page). For in vitro studies, a typical working concentration is 200 nM, applied to cultured PBMCs with 1-hour incubation at 37°C. For animal models, intravenous dosing in the range of 2–10 mg/kg has been shown to induce dose-dependent immune modulation and disease attenuation. Compound is supplied as a powder; dissolve in DMSO (≥29.03 mg/mL) or ethanol (≥69 mg/mL). Store powder at -20°C; avoid repeated freeze-thaw cycles and do not store solutions long-term. For additional protocol optimization in immunoproteasome assays, see "Optimizing Immunoproteasome Assays with ONX-0914 (PR-957)...", which details troubleshooting steps and vendor selection criteria not covered in this review.

Conclusion & Outlook

ONX-0914 (PR-957) stands as a robust, selective tool for investigating immunoproteasome function and cytokine regulation in autoimmunity. Its specificity for LMP7 enables targeted immune modulation with reduced cytotoxicity compared to pan-proteasome inhibitors. As research advances, ONX-0914 will remain a benchmark for immunoproteasome studies and a reference compound for the development of next-generation selective inhibitors. For further details and sourcing, visit the APExBIO ONX-0914 product page.